StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) in a research note published on Sunday morning. The brokerage issued a hold rating on the medical research company’s stock.
Accelerate Diagnostics Stock Performance
AXDX opened at $1.90 on Friday. The business’s 50-day simple moving average is $1.73 and its 200-day simple moving average is $1.32. The company has a market cap of $41.90 million, a P/E ratio of -0.47 and a beta of 0.61. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $6.39.
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.05. The company had revenue of $2.99 million for the quarter, compared to analysts’ expectations of $3.00 million. As a group, analysts predict that Accelerate Diagnostics will post -2.14 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Accelerate Diagnostics
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Further Reading
- Five stocks we like better than Accelerate Diagnostics
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How to Invest in the Best Canadian Stocks
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Stock Sentiment Analysis: How it Works
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.